Recent Progress of Nanomedicine in the Treatment of Alzheimer's Disease

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2023 Jul 17

PMID 37457297

Authors

Liqiang Hu

Yiran Tao

Yanjiao Jiang

Feng Qin

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is the most common cause of memory disruption in elderly subjects, with the prevalence continuing to rise mainly because of the aging world population. Unfortunately, no efficient therapy is currently available for the AD treatment, due to low drug potency and several challenges to delivery, including low bioavailability and the impediments of the blood-brain barrier. Recently, nanomedicine has gained considerable attention among researchers all over the world and shown promising developments in AD treatment. A wide range of nano-carriers, such as polymer nanoparticles, liposomes, solid lipid nanoparticles, dendritic nanoparticles, biomimetic nanoparticles, magnetic nanoparticles, , have been adapted to develop successful new treatment strategies. This review comprehensively summarizes the recent advances of different nanomedicine for their efficacy in pre-clinical studies. Finally, some insights and future research directions are proposed. This review can provide useful information to guide the future design and evaluation of nanomedicine in AD treatment.

Citing Articles

Drug delivery strategies with lipid-based nanoparticles for Alzheimer's disease treatment.

Jang Y, Kang S, Park H, Lee D, Kim J, Kim J J Nanobiotechnology. 2025; 23(1):99.

PMID: 39930497 PMC: 11809104. DOI: 10.1186/s12951-025-03109-3.

Effects and mechanisms of APP and its cleavage product Aβ in the comorbidity of sarcopenia and Alzheimer's disease.

Wu J, Tang J, Huang D, Wang Y, Zhou E, Ru Q Front Aging Neurosci. 2024; 16:1482947.

PMID: 39654807 PMC: 11625754. DOI: 10.3389/fnagi.2024.1482947.

Navigating the nano-bio immune interface: advancements and challenges in CNS nanotherapeutics.

Moulton C, Baroni A, Quagliarini E, Leone L, Digiacomo L, Morotti M Front Immunol. 2024; 15:1447567.

PMID: 39600701 PMC: 11588692. DOI: 10.3389/fimmu.2024.1447567.

Polymeric nanoparticles: A promising strategy for treatment of Alzheimer's disease.

Elmahboub Y, Elkordy A J Taibah Univ Med Sci. 2024; 19(3):549-565.

PMID: 38736898 PMC: 11087974. DOI: 10.1016/j.jtumed.2024.04.004.

Marine-derived Compounds: A Powerful Platform for the Treatment of Alzheimer's Disease.

Arora R, Babbar R, Dabra A, Chopra B, Deswal G, Singh Grewal A Cent Nerv Syst Agents Med Chem. 2024; 24(2):166-181.

PMID: 38305396 DOI: 10.2174/0118715249269050231129103002.

References

Lin Y, Lu Y, Li X . Biological characteristics of exosomes and genetically engineered exosomes for the targeted delivery of therapeutic agents. J Drug Target. 2019; 28(2):129-141. DOI: 10.1080/1061186X.2019.1641508. View

van Dyck C, Swanson C, Aisen P, Bateman R, Chen C, Gee M . Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2022; 388(1):9-21. DOI: 10.1056/NEJMoa2212948. View

Arora S, Kanekiyo T, Singh J . Functionalized nanoparticles for brain targeted BDNF gene therapy to rescue Alzheimer's disease pathology in transgenic mouse model. Int J Biol Macromol. 2022; 208:901-911. DOI: 10.1016/j.ijbiomac.2022.03.203. View

Qu C, Li Q, Su Z, Ip S, Yuan Q, Xie Y . Nano-Honokiol ameliorates the cognitive deficits in TgCRND8 mice of Alzheimer's disease via inhibiting neuropathology and modulating gut microbiota. J Adv Res. 2022; 35:231-243. PMC: 8721355. DOI: 10.1016/j.jare.2021.03.012. View

Simon R, Girod M, Fonbonne C, Salvador A, Clement Y, Lanteri P . Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides. Mol Cell Proteomics. 2012; 11(11):1389-403. PMC: 3494189. DOI: 10.1074/mcp.M112.018861. View

Zhou R, Zhu L, Zeng Z, Luo R, Zhang J, Guo R . Targeted brain delivery of RVG29-modified rifampicin-loaded nanoparticles for Alzheimer's disease treatment and diagnosis. Bioeng Transl Med. 2022; 7(3):e10395. PMC: 9472014. DOI: 10.1002/btm2.10395. View

Mahase E . Alzheimer's disease: FDA approves lecanemab amid cost and safety concerns. BMJ. 2023; 380:73. DOI: 10.1136/bmj.p73. View

Kumari A, Yadav S, Yadav S . Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2009; 75(1):1-18. DOI: 10.1016/j.colsurfb.2009.09.001. View

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

10.

Klajnert B, Cortijo-Arellano M, Cladera J, Bryszewska M . Influence of dendrimer's structure on its activity against amyloid fibril formation. Biochem Biophys Res Commun. 2006; 345(1):21-8. DOI: 10.1016/j.bbrc.2006.04.041. View

11.

Li X, Liu X, Liu X . Self-assembly of colloidal inorganic nanocrystals: nanoscale forces, emergent properties and applications. Chem Soc Rev. 2020; 50(3):2074-2101. DOI: 10.1039/d0cs00436g. View

12.

Li J, Zhang Z, Zhang B, Yan X, Fan K . Transferrin receptor 1 targeted nanomedicine for brain tumor therapy. Biomater Sci. 2023; 11(10):3394-3413. DOI: 10.1039/d2bm02152h. View

13.

Qin F, Luo M, Xiong Y, Zhang N, Dai Y, Kuang W . Prevalence and associated factors of cognitive impairment among the elderly population: A nationwide cross-sectional study in China. Front Public Health. 2022; 10:1032666. PMC: 9713248. DOI: 10.3389/fpubh.2022.1032666. View

14.

Kent S, Spires-Jones T, Durrant C . The physiological roles of tau and Aβ: implications for Alzheimer's disease pathology and therapeutics. Acta Neuropathol. 2020; 140(4):417-447. PMC: 7498448. DOI: 10.1007/s00401-020-02196-w. View

15.

Vangijzegem T, Stanicki D, Laurent S . Magnetic iron oxide nanoparticles for drug delivery: applications and characteristics. Expert Opin Drug Deliv. 2018; 16(1):69-78. DOI: 10.1080/17425247.2019.1554647. View

16.

Bronzuoli M, Iacomino A, Steardo L, Scuderi C . Targeting neuroinflammation in Alzheimer's disease. J Inflamm Res. 2016; 9:199-208. PMC: 5098782. DOI: 10.2147/JIR.S86958. View

17.

Amini M, Abdolmaleki Z . The Effect of Cannabidiol Coated by Nano-Chitosan on Learning and Memory, Hippocampal CB1 and CB2 Levels, and Amyloid Plaques in an Alzheimer's Disease Rat Model. Neuropsychobiology. 2021; 81(3):171-183. DOI: 10.1159/000519534. View

18.

Yang H, Mu W, Wei D, Zhang Y, Duan Y, Gao J . A Novel Targeted and High-Efficiency Nanosystem for Combinational Therapy for Alzheimer's Disease. Adv Sci (Weinh). 2020; 7(19):1902906. PMC: 7539195. DOI: 10.1002/advs.201902906. View

19.

Paliwal R, Paliwal S, Kenwat R, Kurmi B, Sahu M . Solid lipid nanoparticles: a review on recent perspectives and patents. Expert Opin Ther Pat. 2020; 30(3):179-194. DOI: 10.1080/13543776.2020.1720649. View

20.

Bilia A, Nardiello P, Piazzini V, Leri M, Bergonzi M, Bucciantini M . Successful Brain Delivery of Andrographolide Loaded in Human Albumin Nanoparticles to TgCRND8 Mice, an Alzheimer's Disease Mouse Model. Front Pharmacol. 2019; 10:910. PMC: 6713928. DOI: 10.3389/fphar.2019.00910. View